Dopamine and schizophrenia from bench to bedside: Discovery of a striatal co-expression risk gene set that predicts in vivo measures of striatal function
暂无分享,去创建一个
Michael D. Gregory | C. Zink | J. Kleinman | K. Berman | O. Howes | A. Goldman | Qiang Chen | M. Veronese | G. Pergola | William Ulrich | A. Rampino | T. Hyde | E. D’Ambrosio | T. Popolizio | J. Shin | A. Pardiñas | L. Antonucci | R. Passiatore | D. Eisenberg | L. Sportelli | K. Griffiths | Jasmin B. Czarapata | D. Weinberger | Madhur Parihar | Alessandro Bertolino
[1] Elizabeth K. Baker,et al. Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study , 2022, Translational Psychiatry.
[2] H. Cao,et al. Neural substrates of reward anticipation and outcome in schizophrenia: a meta-analysis of fMRI findings in the monetary incentive delay task , 2022, Translational Psychiatry.
[3] G. Pergola,et al. Lessons Learned From Parsing Genetic Risk for Schizophrenia Into Biological Pathways , 2022, Biological Psychiatry.
[4] S. Stahl,et al. Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic. , 2022, Trends in pharmacological sciences.
[5] Michael F. Green,et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia , 2022, Nature.
[6] Michael D. Gregory,et al. Clinical correlation but no elevation of striatal dopamine synthesis capacity in two independent cohorts of medication-free individuals with schizophrenia , 2021, Molecular Psychiatry.
[7] Louise A. Huuki,et al. Single-nucleus transcriptome analysis reveals cell-type-specific molecular signatures across reward circuitry in the human brain , 2021, Neuron.
[8] Richard F. Betzel,et al. Brain network dynamics during working memory are modulated by dopamine and diminished in schizophrenia , 2021, Nature Communications.
[9] P. Conn,et al. Targeting muscarinic receptors to treat schizophrenia , 2021, Behavioural Brain Research.
[10] Harper B. Fauni,et al. A computational tool (H-MAGMA) for improved prediction of brain disorder risk genes by incorporating brain chromatin interaction profiles , 2020, Nature Neuroscience.
[11] F. Turkheimer,et al. The relationship between grey matter volume and striatal dopamine function in psychosis: a multi-modal 18F-DOPA PET and voxel-based morphometry study , 2019, Molecular Psychiatry.
[12] Andrew E. Jaffe,et al. Prefrontal Coexpression of Schizophrenia Risk Genes Is Associated With Treatment Response in Patients , 2019, Biological Psychiatry.
[13] T. Raj,et al. Tensor decomposition of stimulated monocyte and macrophage gene expression profiles identifies neurodegenerative disease-specific trans-eQTLs , 2018, bioRxiv.
[14] Daniel R Weinberger,et al. Identification and prioritization of gene sets associated with schizophrenia risk by co-expression network analysis in human brain , 2018, bioRxiv.
[15] Y. Saeys,et al. A comprehensive evaluation of module detection methods for gene expression data , 2018, Nature Communications.
[16] O. Howes,et al. Defining the Locus of Dopaminergic Dysfunction in Schizophrenia: A Meta-analysis and Test of the Mesolimbic Hypothesis , 2017, Schizophrenia bulletin.
[17] Nicola J. Rinaldi,et al. Genetic effects on gene expression across human tissues , 2017, Nature.
[18] R. Gur,et al. Striatal dysfunction in patients with schizophrenia and their unaffected first-degree relatives , 2017, Schizophrenia Research.
[19] J. Kwon,et al. Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study , 2017, Neuropsychopharmacology.
[20] Robin M. Murray,et al. The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia , 2017, Biological Psychiatry.
[21] Hyejung Won,et al. The road to precision psychiatry: translating genetics into disease mechanisms , 2016, Nature Neuroscience.
[22] Nora C. Vetter,et al. Polygenic Risk of Psychosis and Ventral Striatal Activation During Reward Processing in Healthy Adolescents. , 2016, JAMA psychiatry.
[23] M. McCarthy,et al. Tensor decomposition for multi-tissue gene expression experiments , 2016, Nature Genetics.
[24] A. Grace. Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression , 2016, Nature Reviews Neuroscience.
[25] Benjamin A. Logsdon,et al. Gene Expression Elucidates Functional Impact of Polygenic Risk for Schizophrenia , 2016, Nature Neuroscience.
[26] G. Juckel. Inhibition of the reward system by antipsychotic treatment , 2016, Dialogues in clinical neuroscience.
[27] S. Horvath,et al. Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap , 2016, Science.
[28] E. Heerey,et al. The nature of anhedonia and avolition in patients with first-episode schizophrenia , 2015, Psychological Medicine.
[29] P. Calabresi,et al. Direct and indirect pathways of basal ganglia: a critical reappraisal , 2014, Nature Neuroscience.
[30] R. Murray,et al. Schizophrenia: an integrated sociodevelopmental-cognitive model , 2014, The Lancet.
[31] A. Meyer-Lindenberg,et al. Ventral striatal activation during attribution of stimulus saliency and reward anticipation is correlated in unmedicated first episode schizophrenia patients , 2012, Schizophrenia Research.
[32] Mark Slifstein,et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. , 2012, Archives of general psychiatry.
[33] S. Kapur,et al. Alterations of the Brain Reward System in Antipsychotic Naïve Schizophrenia Patients , 2012, Biological Psychiatry.
[34] R. Murray,et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study , 2011, Molecular Psychiatry.
[35] T. van Amelsvoort,et al. Dopaminergic modulation of the human reward system: a placebo-controlled dopamine depletion fMRI study , 2011, Journal of psychopharmacology.
[36] Fabio Sambataro,et al. Genetically Determined Measures of Striatal D2 Signaling Predict Prefrontal Activity during Working Memory Performance , 2010, PloS one.
[37] H. Heinze,et al. Mesolimbic Functional Magnetic Resonance Imaging Activations during Reward Anticipation Correlate with Reward-Related Ventral Striatal Dopamine Release , 2008, The Journal of Neuroscience.
[38] A. Christopoulos,et al. Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia , 2008, Proceedings of the National Academy of Sciences.
[39] Craig Mallinckrodt,et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. , 2008, The American journal of psychiatry.
[40] T. McGlashan,et al. Striatal Dopamine Synthesis in First-degree Relatives of Patients with Schizophrenia , 2008, Biological Psychiatry.
[41] Leonardo Fazio,et al. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory , 2007, Proceedings of the National Academy of Sciences.
[42] B. Gallhofer,et al. The Influence of Antipsychotic Treatment on Brain Reward System Reactivity in Schizophrenia Patients , 2007, Pharmacopsychiatry.
[43] Brian Knutson,et al. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics , 2006, Psychopharmacology.
[44] Arno Villringer,et al. Dysfunction of ventral striatal reward prediction in schizophrenia , 2006, NeuroImage.
[45] S. Horvath,et al. Statistical Applications in Genetics and Molecular Biology , 2011 .
[46] A. Meyer-Lindenberg,et al. Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional connectivity in schizophrenia. , 2005, Archives of general psychiatry.
[47] Brian Knutson,et al. Amphetamine Modulates Human Incentive Processing , 2004, Neuron.
[48] A. Meyer-Lindenberg,et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia , 2002, Nature Neuroscience.
[49] C. Nicholson,et al. Amphetamine Distorts Stimulation-Dependent Dopamine Overflow: Effects on D2 Autoreceptors, Transporters, and Synaptic Vesicle Stores , 2001, The Journal of Neuroscience.
[50] Alessandro Usiello,et al. Distinct functions of the two isoforms of dopamine D2 receptors , 2000, Nature.
[51] R. V. Van Heertum,et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[52] Alan C. Evans,et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[53] D. Weinberger. Implications of normal brain development for the pathogenesis of schizophrenia. , 1987, Archives of general psychiatry.
[54] S. Thiemann,et al. Depression, Parkinsonian Symptoms, and Negative Symptoms in Schizophrenics Treated With Neuroleptics , 1987, The Journal of nervous and mental disease.
[55] S H Snyder,et al. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs , 1976, Science.
[56] Marie-Claude Asselin,et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. , 2009, Archives of general psychiatry.
[57] Paul J. Harrison,et al. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence , 2005, Molecular Psychiatry.